When economizing on agency spend, a key question needs to be answered: "Are you getting great value for your promotion?"
SENIOR VICE PRESIDENT, DIRECTOR OF CLIENT SERVICES | ABELSONTAYLOR
Whenever I discuss the issue of economizing on agency spend, two key questions need to be answered. First: "Are you getting great value for your promotion?" (That is, does it work as well as it could?) If the answer is no, a savvy and cost-conscious marketer should focus on the quality of the core promotion first. Economy comes from cutting programs that don't work, not by cutting the margins of a trusted partner who is doing the job you ask of them.
Jay Carter
The second question is "Are my processes as efficient as they can be?" While every organization needs to be effective in gaining the advice and consent of a medical-regulatory-legal team, frequently the number of steps taken are far more extensive than productivity would permit. For a large pharma client on a billion-dollar brand, a Six Sigma process was undertaken jointly by the client and AbelsonTaylor. It uncovered inefficiencies that, when addressed, reduced process costs by 17 percent. The main culprits? Poor initial direction by unseasoned brand managers and a need by junior staff to have perfectly clean promotional materials produced for each escalating review by their management. If senior marketers want to cut their costs, they can do so by undertaking efficiency training for their promotions staff on how to cut the waste out of their own process.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.